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ABSTRACT
Background: Common prenatal ailments negatively impact performance of activities
of daily living and it has been proposed that the use of dynamic elastomeric fabric
orthoses, more commonly referred to as compression garments, during pregnancy
might aid in the reduction of pain from these ailments, allowing for improved
functional capacity. However, the effectiveness of such garments in this context has
not been established. This study aims to determine whether compression shorts are
effective and thermally safe in the prevention and management of prenatal pelvic and
low back pain (LBP).
Method: A prospective quasi-experimental controlled study using parallel groups
without random allocation was conducted, involving 55 childbearing women
(gestational weeks 16–31) recruited from hospital and community-based maternity
care providers. The compression shorts group (SG) wore SRC Pregnancy Shorts in
addition to receiving usual care. The comparison group (CG) received usual care
alone. Primary outcome measures—Numeric Pain Rating Scale (NPRS) and Roland
Morris Disability Questionnaire (RMDQ) and secondary measures Pelvic Floor
Impact Questionnaire - 7 (PFIQ-7) and SF-36 Short Form Health Survey—were
assessed fortnightly over 6-weeks for both groups. The compression SG self-assessed
daily their body temperatures to monitor thermal impact. Data analysis involved
descriptive analyses of the primary and secondary outcome measures scores by group
and time-point, and multivariable linear regressions to assess between-group
differences in change scores at 6-weeks from baseline while controlling for baseline
factors.
Results: After controlling for baseline scores, gestational weeks and parity,
statistically signiﬁcant differences in NPRS and RMDQ change scores between
groups were in favour of the compression SG. At 6-weeks, mean (SD) NPRS change
scores in the compression SG and CG were signiﬁcantly different, at -0.38 (2.21) and
2.82 (2.68), respectively, p = 0.003. Mean (SD) RMDQ change scores in the
compression SG and CG were also signiﬁcantly different, at 0.46 (3.05) and
3.64 (3.32), respectively, p = 0.009. A total of 883 (99.7%) of the reported daily
self-assessed body temperatures ranged between 35.4 and 38.0 C when wearing the
compression shorts. At 6-weeks, mean (SD) PFIQ-7 and SF-36 change scores in the
compression SG and CG were not signiﬁcantly different.
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INTRODUCTION
The two most commonly reported prenatal problems are low back pain (LBP) and
pelvic girdle pain (PGP) (Fitzgerald & Mallinson, 2012; Pennick & Liddle, 2013). An
estimated 50–70% of women report LBP during pregnancy (Colla, Paiva & Thomas, 2017;
Hughes et al., 2018; Ho et al., 2009a; Wang et al., 2005). On this basis, LBP is quite often
considered ‘normal’ during pregnancy, but women report that it interferes with their
activities of daily living (Colla, Paiva & Thomas, 2017; Hughes et al., 2018). PGP during
pregnancy is estimated to range in prevalence from 24% to 50%, with the cited reason for
this range being there is variability in how PGP is deﬁned, how physical assessments to
identify PGP are performed and how it is reported (Clinton et al., 2017; Fitzgerald &
Mallinson, 2012; Walters, West & Nippita, 2018). Research suggests the two common
prenatal ailments negatively impact activities of daily living (Clinton et al., 2017) and, in
Scandinavian countries, they have been found to account for a large proportion of
sick-leave taken by pregnant women or postnatal women returning to work (Backhausen
et al., 2018; Aldabe, Milosavljevic & Bussey, 2012; Larsen et al., 1999; Stuge, Hilde &
Vøllestad, 2003).
Abnormal pelvic ﬂoor muscle function can affect the timing of voluntary contraction
and relaxation of these muscles and occurs in women whose primary complaints are LBP
or PGP (Fitzgerald & Mallinson, 2012). For this reason, many current treatments for
prenatal pelvic pain incorporate interventions to address these abnormalities in muscle
function (Fitzgerald & Mallinson, 2012). Multimodal interventions incorporating, for
example, physiotherapy, pelvic support belt (Hammer et al., 2015) and/or complementary
medicine (described in the literature as massage therapy, acupuncture, relaxation, yoga
and hypnosis (Waterﬁeld et al., 2015; Field, 2008)) have been found to be effective in
relieving prenatal LBP and PGP (George et al., 2013; Ho et al., 2009b; Pennick & Liddle,
2013; Walters, West & Nippita, 2018).
Pelvic support belts constitute a type of intervention used to provide relief from several
common complaints during pregnancy. Research has found 83% of women with PGP or
LBP experience reduced posterior pelvic pain when wearing a pelvic support belt, with
only 12% experiencing no relief, and 5% reporting they felt worse (Depledge et al., 2005).
Furthermore, training of the diagonal trunk muscle system, (speciﬁcally internal and
external oblique muscles, latissimus dorsi, multiﬁdus and gluteus maximus), and the use of
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pelvic support belts together assist women to achieve greater reductions in symptoms than
are typically achieved by spontaneous resolution alone (Mens, Snijders & Stam, 2000;
Stuge, Holm & Vøllestad, 2006). Pelvic support belts provide often-needed support to
reduce prenatal pain and so such belts tend to be an early intervention provided to manage
pain in this context (Bertuit et al., 2018; Carr, 2003; Clinton et al., 2017; Vleeming et al.,
2008). However, other factors need to be considered when prescribing pelvic support belts,
given the target population is pregnant women. These factors include levels of compliance
in wearing the belt, positioning of the belt, accuracy in sizing, required compression
location to stimulate stabilizing muscles, and effects on core body temperature (a special
consideration, as this needs to be carefully regulated during pregnancy) (Damen et al.,
2002; Ho et al., 2009b).
Earlier studies indicated that pelvic support belts were associated with poor compliance
due to ‘garment-related problems including skin irritation from the seams and fasteners,
discomfort from rolled up and buckled back panel during sitting and unsatisfactory
adjustability, ﬁtting for back support and the noise of Velcro tape’ (Ho et al., 2009a).
Therefore, a valuable direction for future research would be to investigate whether the
use of compression garments might be superior to the use of pelvic support belts for
therapeutic purposes in these populations, since research on compression garments has
indicated an improved venous blood ﬂow because of its compressive effects (Houghton,
Dawson & Maloney, 2009); it can be worn under daily attire (Houghton, Dawson &
Maloney, 2009); and its ability to decrease muscle oscillation which in turn may improve
neurotransmission and mechanics (Doan et al., 2003).
Compression garments need to be clearly deﬁned and described in research designed
to test their effectiveness, feasibility and acceptability. Descriptions of speciﬁc garment
types should identify the method of application of the garment, the garment design, the
garment materials and the pressure applied by the garment (MacRae et al., 2012), so that
study results can be validly interpreted, synthesised, compared and implemented. Review
of the literature on compression garments is currently challenging, as it is difﬁcult to
compare and draw conclusions about the garments used in different studies because
studies have used various garment types and application procedures (Ho et al., 2009a). The
heterogeneity in designs and materials used in previous studies makes valid comparisons
and synthesis of results from those studies difﬁcult. For example, some studies have
used standard compression bandages ranging in number of layers, others have used
compression stockings or hosiery, and still other studies have used a sports compression
garment. Furthermore, compression garments are variously deﬁned and can be labelled
using terms such as ‘maternity support garments’, ‘lumbopelvic support garments’,
‘pelvic stability’ or ‘support belts.’ A deﬁned classiﬁcation system for grading of the
compression provided by garments is lacking, and design materials have been inconsistent.
Therefore, the literature suggests the term dynamic elastomeric fabric orthoses (DEFOs) to
be used when referring to compression garments as they are designed to apply consistent
compression through tailored elastomeric panels strategically positioned to address
common prenatal ailments (Sawle, Freeman &Marsden, 2016), minimising variability in
garments used in this population.
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The available research on DEFOs hints that use of DEFOs during pregnancy might
aid in the reduction of pain associated with common musculoskeletal ailments, allowing
for a potential increase in functional capacity. However, deﬁnitive evidence of such
an effect is lacking. Consistent with the need for maternity care providers to utilise
evidenced-based practice to provide effective and safe interventions for their patients,
it is imperative that further research is conducted on DEFOs to assess their effectiveness
in reducing pain and increasing functional capacity in pregnant women and to further
conﬁrm their thermal safety in this population, in order to guide their use in practice.
On this basis, the aims of this study were to examine the effectiveness of a speciﬁc
DEFOs (SRC Pregnancy Shorts, manufactured by SRC Health Pty Ltd, Port Melbourne,
Australia) for reducing prenatal pain and associated disability arising from the pelvic girdle
and lower back and to further assess the thermal safety of these compression shorts when
they were worn during pregnancy.
Based on published evidence, it was hypothesised that: (i) the use of DEFOs would
be considered an effective therapeutic intervention to decrease prenatal PGP and LBP
allowing an increase in functional capacity; (ii) perceived quality of life would improve
with the use of DEFOs; and (iii) DEFOs will not affect maternal core temperature and
therefore, would be thermally safe to wear during pregnancy.
METHOD
Ethics
Ethics approval for the study was granted by the Queensland Health Ofﬁce of Human
Research Ethics Committee (HREC/14/QGC/200) and Bond University Human Research
Ethics Committee (BUHREC: RO1800c).
Study design
A prospective quasi-experimental controlled study using parallel groups without random
allocation was conducted and involved two groups: a compression shorts group (SG),
which received usual physiotherapy and broader health care and wore SRC Pregnancy
Shorts (SRC Health Pty Ltd, Melbourne, Australia), and a comparison group (CG), which
received only usual physiotherapy and broader health care.
A randomised controlled (RCT) trial was initially proposed; however, following
consideration of relevant ethical issues, consultation with the ethics committees and
receipt of their considered recommendations, it was decided to allow participants the
opportunity to decide which group they preferred to participate in. The key concern of
the ethics committee was withholding of a possibly needed intervention from pregnant
women. While a prospective quasi-experimental controlled study without random
allocation is less rigorous than a randomised design, the use of a parallel CG meant
that the study methodology was as rigorous as possible given the concerns of the ethics
committee. As our study did not involve ‘unapproved’ therapeutic goods, it was not
subject to registration as a clinical trial under either clinical trial notiﬁcation scheme or
clinical trial exemption according to the Australian Government Department of Health
Therapeutic Goods Administration (TGA) (2018).
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Participant recruitment
Participant recruitment took place at a metropolitan hospital, local university and the
facilities of maternity care providers on the Gold Coast, Australia. Recruitment occurred
over a 2-year period, from March 2015 to March 2017. Recruitment strategies consisted
of general information sheets posted in maternity care providers’ ofﬁces, information
provided online and in newspaper articles, and referral from other participants involved in
the study. Eligibility criteria for participation included: female, age 18–50 years, gestational
weeks 16–31 at time of recruitment, diastasis of the rectus abdominis muscle (DRAM)
less than six cm and complaining of LBP and/or PGP. Participants were not excluded if they
were experiencing pelvic oedema, pelvic ﬂoor dysfunction, urinary or faecal incontinence, or
mild varicose veins. A sample size calculation indicated that a total sample size of 47 was
required for a multivariable linear regression with four predictors to detect a large effect size
(Cohen’s f 2 = 0.35) with a statistical power of 80% and signiﬁcance level of 0.025 for the two
primary outcomes. The sample size was inﬂated to 60 to allow for 20% dropouts.
Before commencement of recruitment for the study, four information sessions were
given to the physiotherapists, nurses and midwifery staff at maternity care facilities that
were involved in recruitment. These information sessions were used to explain the study
and its procedures, and to discuss any questions or concerns about the research, the
DEFOs, how to correctly ﬁt the DEFOs, and how the recruitment, consent and
enrolment processes were to be executed. Recruitment was conducted by the maternity
care providers and once a person agreed to be involved in the study and with the
prospective participant’s consent, their contact information was forwarded to the chief
investigator. The chief investigator contacted the prospective participant, provided
further information on the study and gained their voluntary, written informed consent if
they agreed to participate. The participant then chose their involvement preference
within the research study, in either the SG or CG. Subsequently, the participant was
allocated a random number to use when accessing the survey (discussed further below).
Participants were provided with the chief investigator’s contact details as part of the
information and consent process, in case assistance was needed at any time.
Intervention
The intervention for the SG group consisted of provision and wearing of SRC Pregnancy
Shorts, together with their usual prenatal physiotherapy and broader health care.
Participation in the study had no inﬂuence on their usual care. Participants in the SG were
measured and ﬁtted for the compression shorts and provided with one pair of compression
shorts to wear daily for a minimum of 8 h per day during their pregnancy from date of
recruitment for a total of 6-weeks. It was expected that they were to wash and dry the
compression shorts as needed to enable the participant to wear them daily. Participants in
the SG recorded daily their levels of compliance indicating the number of days and the
average number of hours the SRC Pregnancy Shorts were worn daily over 2-weeks and
reasons for any lack of compliance.
SRC Pregnancy Shorts were speciﬁcally designed for pregnant women and are available
in seven sizes, ranging from double extra-small to double extra-large. The SRC Pregnancy
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Shorts were constructed of a breathable warp knit fabric with a power mesh lining design
using true cross compression so that no compression was lost during activity, as each
fabric layer was cut on a different plane (SRC Health Pty Ltd, 2017) (Fig. 1).
The SG was instructed on how to wear the garment, how to adjust it for size as needed,
and how to wash and care for the garment. More speciﬁcally, the SG participants were
educated on wearing the garment so that the garment was ﬁrm around the pelvis, not tight
or restrictive, and comfortable. Participants were instructed to use the adjustable tabs
on each side of the garment, gradually releasing one side at a time until a comfortable ﬁt
was achieved.
Figure 1 SRC Pregnancy Shorts—the DEFOs used by the SG. Available at https://www.srchealth.com/
src-pregnancy-shorts-black. Full-size DOI: 10.7717/peerj.7080/ﬁg-1
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The SG received a handout explaining precautions to take while wearing the garment
(i.e. DEFOs to be ﬁrm and comfortable, not tight or restrictive and must sit below the
belly), and any clinical presentations that required immediate cessation of use and to
be reviewed immediately by their maternity-care provider (i.e. garment to be removed if
body temperature was greater than 38 C as this may indicate an illness). Whilst previous
literature suggests that DEFOs do not increase core temperature, in order to monitor
any possible risk, the SG received a handout explaining the precautions in detail. The
participants wore the compression shorts daily for a minimum of 8 h per day unless
clinical concerns (described above) indicated they should remove the garment and notify
their maternity care provider.
The CG continued their usual prenatal physiotherapy care and broader health care, and
participation in the study had no inﬂuence on their usual care. Participants in the CG
did not receive a compression garment at any time. All participants were asked to notify
the chief investigator on the research team should they be required to wear a DEFOs
during their usual care, and if so, they would be excluded from the study.
For the SG and the CG, standard physiotherapy care was dependent on the individual
needs of the participant and may include any of the following: joint mobilisations,
massage therapy, exercise therapy, education, ergonomic and activities of daily living
modiﬁcations, and general advice.
Outcome measures
A baseline questionnaire completed online for the SG and CG included a brief demographic
survey asking questions such as the group they were in, their age, gestational week,
gravida/parity, and whether they had experienced DRAM (previous or current) or
prenatal ailments or received treatment for either. SG and CG completed two primary
outcome measures, the Numeric Pain Rating Scale (NPRS) (Huskissin, 1974) and the
Roland Morris Disability Questionnaire (RMDQ) (Morris, 1983), and two secondary
outcome measures, the Pelvic Floor Impact Questionnaire - 7 (PFIQ-7) (Barber, Walters &
Bump, 2005), and the SF-36 Short Form Health Survey (Ware & Sherbourne, 1992;
Marosszeky, 2014) each fortnight, online. The NPRS is an 11-item scale that subjectively
measures the intensity of pain (Huskissin, 1974). Looking at aspects such as functional
mobility, pain and activities of daily living, the RMDQ is a 24-item self-report questionnaire
that assesses how LBP affects functional activities (Morris, 1983). The PFIQ-7 is a 7-question
self-report questionnaire composed of three subscales that assess the impact of pelvic
ﬂoor functioning or dysfunction on quality of life, daily activities and emotional health
(Barber, Walters & Bump, 2005). The SF-36 short form health survey is a 36-item
questionnaire that measures quality of life across eight domains that are physically and
emotionally based (Ware & Sherbourne, 1992; Marosszeky, 2014). The SG group had an
additional secondary outcome measure, daily self-assessed body temperatures.
Data collection
Data were collected online via a link to the anonymous questionnaire at a time and place
that was convenient for the participant. Responses for each participant in the SG and CG
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were linked across time-points (baseline, 2 weeks, 4 weeks and 6 weeks) using the
participant’s random identiﬁcation number. SG and CG participants completed the
primary and secondary outcome measures, (NPRS, RMDQ, PFIQ-7 and SF-36), each
fortnight, online. In addition, the SG self-assessed their body temperatures four times each
day while wearing the compression shorts (at 2, 4, 6 and 8-h time points following donning
of the compression shorts) and documented their daily average for their survey
responses online for their body temperature. If the participant in the SG had to cease wearing
the compression shorts at any time during any day due to their body temperature being
greater than 38.0 C, the highest body temperature was recorded for that day. The SG
indicated in the online survey how their daily body temperature was measured when wearing
the compression shorts, such as by measuring oral, axillary, tympanic, or rectal temperature.
Data analysis
Data were analysed using IBM SPSS software (Version 24; Armonk, NY, USA). Descriptive
statistics were reported as mean (SD) for normally distributed continuous variables and
counts (%) for categorical variables. The assumption of normality for primary and
secondary outcome measures was assessed by Q-Q plots, histograms and the Shapiro–
Wilk test. Summary statistics were also produced for the different time-points (baseline, 2
weeks, 4 weeks, 6 weeks) for the raw primary and secondary outcome measures and for the
change scores (from baseline) on these measures. Univariable regression analyses were
conducted to assess the effects on primary and secondary outcome measures of factors
including treatment group, baseline score, age category, gestational weeks and parity.
Factors which were signiﬁcant at the 0.10 level of signiﬁcance and/or clinically important
were selected for inclusion in subsequent multivariable analyses.
Multivariable linear regression analyses were used to examine effects at week 6 of group
and other above-mentioned factors on the primary outcome measures, NPRS and RMDQ,
and secondary outcome measures, PFIQ-7 and SF-36, in order to test the effects of
wearing the SRC Pregnancy Shorts on a participant’s pain, quality of life and functional
capacity while accounting for baseline score, gestational week and parity. Supplementary
analyses included assessments of observed effects at weeks 2 and 4. The main results
are presented as regression coefﬁcients with 95% conﬁdence intervals (CIs), and p-values,
and the proﬁles of the mean change scores over time were graphically presented. The
criterion for statistical signiﬁcance in the regression analyses was set at the 0.025 level for
the primary outcome measures and at the 0.05 level for the secondary outcome measures
and supplementary analyses.
RESULTS
Of the 55 pregnant women who consented to participate and received their allocated
intervention, 12 women were lost to follow-up in the SG and six in the CG by the ﬁnal
time-point (6 weeks) (Fig. 2). No participants were excluded from the CG based on the
criteria that if a DEFOs was prescribed the participant would be excluded from the study.
Table 1 describes the demographic characteristics of the participants, by group.
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Participant demographic data were similar in the SG and CG when considering age
category, whether it was the participant’s ﬁrst pregnancy, gravida, parity and gestational
weeks. DRAM only affected a very small number of participants in each group (SG (n = 2)
Figure 2 Participant ﬂow diagram. Full-size DOI: 10.7717/peerj.7080/ﬁg-2
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and CG (n = 3)) and so was excluded as a predictor variable from the subsequent
regression analyses. In the few participants who reported DRAM, differences were
identiﬁed between the SG and CG in the size of DRAM at baseline (mean (SD) of 0.42
Table 1 Baseline demographic and clinical characteristics for the 55 pregnant participants.
Characteristics Compression shorts group
SGa (n = 38)
Comparison group
CGb (n = 17)
Age category
23–30 12 (31.5) 2 (11.8)
31–34 15 (39.5) 12 (70.5)
35–42 11 (28.9) 3 (17.6)
Gestational weeks mean (SD) 23.7 (4.9) 25.3 (4.0)
First pregnancy
Yes 15 (39.5) 6 (35.3)
Gravida
1 15 (39.5) 14 (82.3)
2 13 (34.2) 3 (17.6)
3 9 (23.7) 0 (0.0)
4 0 (0.0) 0 (0.0)
5 1 (2.6) 0 (0.0)
Parity
0 15 (39.5) 6 (35.3)
1 16 (42.1) 10 (58.8)
2 7 (18.4) 0 (0.0)
3 0 (0.0) 0 (0.0)
4 0 (0.0) 1 (5.9)
Current DRAMc
Yes 2 (5.3) 3 (17.6)
Current DRAM treatment
Tubing band 0 (0.0) 2 (11.8)
Pilates 0 (0.0) 1 (5.9)
Previous DRAM
Yes 28 (73.7) 12 (70.6)
Previous DRAM treatment
Physiotherapy 5 (13.2) 1 (5.9)
Tubing band 2 (5.3) 2 (11.8)
HEPd 6 (15.8) 1 (5.9)
Pilates 2 (5.3) 1 (5.9)
Acupuncture 0 (0.0) 0 (0.0)
Surgery 0 (0.0) 0 (0.0)
None 3 (7.9) 1 (5.9)
Notes:
Data are counts (n(%)) unless otherwise speciﬁed.
a SG wore SRC pregnancy shorts (SRC Health Pty Ltd., Port Melbourne, Australia) and received usual care.
b CG received usual care only.
c Diastasis of the rectus abdominis muscle (DRAM).
d Home exercise program (HEP).
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(1.81) and 2.67 (1.15) cm, in the SG and CG, respectively) and the types of treatment
received for DRAM. Many women presented clinically at baseline with LBP (19 in the SG
and 12 in the CG) and PGP (29 in the SG and 10 in the CG), as well as reporting other
common pregnancy related ailments like urinary incontinence (Table 2).
Between time points (baseline to 2 weeks, 2–4 weeks and 4–6 weeks), the SG wore the
compression shorts on average 10 h per day, meeting the compliance goal of a minimum of
8 h per day over a 14-day period. Those participants who did not wear the garments
for a minimum of 8 h per day reported non-compliance reasons such as the garment
being too hot or uncomfortable, and the participant not liking the appearance of the
compression shorts when worn under work attire and summer dresses. The participants
wore the compression shorts on average 10 out of 14 days, identifying reasons for
non-compliance in days worn such as ‘forgot,’ ‘uncomfortable,’ ‘did not ﬁt under work
attire,’ and ‘the garment needed to be washed.’ Non-compliance in wearing the compression
shorts increased as the women entered later weeks of their pregnancy. In the ﬁnal 2-week
time period, between weeks 4 and 6, SG participants wore the compression shorts for a
mean of 10.2 h per day, on 9.4 days out of 14.
Assessment of the distributions of continuous variables indicated that the assumption of
normality was met across all outcome measures. Table 3 provides raw data and change
scores for the primary outcome measures, NPRS and RMDQ, and Table 4 displays raw
data and change scores for the secondary outcome measures, PFIQ-7, SF36-PCS and
SF36-MCS. Table 5 shows the estimated regression coefﬁcients from the multivariable
linear regression, to show the effects at week 6 of wearing the compression shorts on the
changes in primary outcome measures, NPRS and RMDQ, after adjusting for baseline
covariates.
The multivariable linear regression model detected statistically signiﬁcant differences
between the SG and CG in NPRS change scores at two of the time points, 4 weeks and
6 weeks, with the SG group reporting substantially better pain relief than the CG group.
At 6 weeks, the SG group experienced a reduction in mean (SD) NPRS pain score
(-0.38 (2.21)) from baseline levels, whereas the CG group suffered an increase in pain
Table 2 Frequencies (%) of participants with speciﬁc prenatal ailments at baseline.
Prenatal ailment Compression shorts
group—SG (n = 38)
Comparison
group—CG (n = 17)
Low back pain 19 (50.0) 12 (31.6)
Pelvic girdle pain 29 (76.3) 10 (58.8)
DRAM 5 (13.2) 0 (0.0)
Vulval varicosities 13 (34.2) 1 (5.9)
Urinary incontinence 2 (5.3) 3 (17.6)
Muscle weakness 4 (10.5) 5 (29.4)
None 1 (2.6) 1 (5.9)
Othera 8 (21.1) 6 (35.3)
Note:
a Other included self-reported aching thighs, sciatic pain, leg varicose veins, thoracic and rib cage pain, hip pain, vaginal
discharge, leg cramps and swelling of hands and feet.
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(2.82 (2.68)) over this same 6-week period (Table 3; Fig. 3). After controlling for baseline
pain, age, gestational weeks and the number of previous births, 6 weeks after commencing
use of the DEFOs there was a statistically signiﬁcant difference in NPRS change scores
Table 3 Raw data and change scores for NPRS and RMDQ.
Time Raw data scores Change scoresa
n SG Mean (SD) n CG Mean (SD) n SG Mean (SD) n CG Mean (SD)
NPRSb
Baseline 38 4.21 (2.36) 17 2.94 (2.14)
Week 2 31 3.03 (2.12) 15 3.27 (2.28) 31 -1.19 (1.89) 15 0.40 (1.35)
Week 4 30 3.33 (2.56) 14 4.86 (2.63) 30 -0.97 (2.31) 14 1.86 (2.11)
Week 6 26 3.81 (2.59) 11 6.09 (2.30) 26 -0.38 (2.21) 11 2.82 (2.68)
RMDQc
Baseline 38 4.05 (5.21) 17 4.18 (2.43)
Week 2 31 2.97 (3.53) 15 5.00 (3.80) 31 -0.77 (4.80) 15 1.20 (2.91)
Week 4 30 3.87 (5.04) 14 6.21 (4.79) 30 0.03 (3.44) 14 2.37 (3.83)
Week 6 26 4.31 (6.27) 11 7.64 (3.85) 26 0.46 (3.05) 11 3.64 (3.32)
Notes:
a Negative change score indicates a reduction in pain or disability from baseline.
b Numeric Pain Rating Scale (NPRS) is scored 0 (no pain) to 10 (worst pain imaginable).
c Roland Morris Disability Questionnaire (RMDQ) is scored 0 (no disability) to 24 (maximum disability).
Table 4 Raw Data and Change Scores for PFIQ-7, SF36-PCS and SF36-MCS.
Time Raw data scores Change Scoresa
n SG Mean (SD) n CG Mean (SD) n SG Mean (SD) n CG Mean (SD)
PFIQ-7b
Baseline 38 43.73 (30.34) 17 37.25 (47.21)
Week 2 31 40.37 (31.16) 15 42.22 (48.82) 31 -1.25 (14.89) 15 3.81 (24.76)
Week 4 30 39.21 (39.72) 14 48.30 (52.46) 30 -3.65 (28.54) 14 7.14 (24.76)
Week 6 26 41.67 (39.00) 11 50.22 (51.79) 26 -0.46 (24.30) 11 2.17 (25.85)
SF36- PCSc
Baseline 38 30.23 (4.17) 17 22.13 (6.44)
Week 2 31 27.43 (5.35) 15 23.22 (6.23) 31 -2.31 (6.25) 15 1.87 (7.42)
Week 4 30 28.64 (4.65) 14 28.44 (3.41) 30 -0.52 (5.32) 14 7.55 (6.10)
Week 6 26 28.87 (6.27) 11 30.39 (4.41) 26 -0.23 (6.95) 11 9.64 (5.74)
SF36-MCSd
Baseline 38 33.97 (6.32) 17 33.51 (6.53)
Week 2 31 33.78 (5.73) 15 33.89 (7.65) 31 -0.37 (4.65) 15 0.09 (6.85)
Week 4 30 22.23 (5.62) 14 41.29 (9.78) 30 -12.14 (7.99) 14 7.76 (10.49)
Week 6 26 32.83 (6.06) 11 33.05 (8.59) 26 -1.27 (5.49) 11 0.62 (8.74)
Notes:
a A negative change score indicates a reduction in perceived effect of pelvic dysfunction on quality of life or an increase in
level of functioning from baseline.
b Pelvic Floor Impact Questionnaire - 7 (PFIQ-7) is scored 0 (lowest perceived effect of pelvic ﬂoor dysfunction on
quality of life) to 300 (greatest perceived impact of pelvic ﬂoor dysfunction on quality of life).
c SF-36 Physical Component Summary (SF-36 PCS) is the mean percentage score from all of the physically relevant
questions (0% worst to 100% best possible level of functioning).
d SF-36 Mental Component Summary (SF-36 MCS) is the mean percentage score from all of the emotionally relevant
questions (0% worst to 100% best possible level of functioning).
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Table 5 Estimated regression coefﬁcients from the multivariable linear regression to show the effect
at week 6 of wearing compression shorts (n = 26) when compared to the control condition (n = 11) on
the change in primary outcome measures, NPRS and RMDQ, after adjusting for baseline covariates.
Variable Regression coefﬁcient 95% Conﬁdence interval p-value
NPRS
Constant 4.03 [−1.12–9.19] 0.121
Groupa -2.84 [−4.63 to −1.04] 0.003c
Baseline NPRS score -0.41 [−0.79 to −0.04] 0.032
Gestational weeksb 0.003 [−0.18–0.19] 0.970
Previous number of children 0.09 [−1.01–1.18] 0.875
RMDQ
Constant 4.09 [−3.14–11.32] 0.258
Groupa -3.39 [−5.89 to −0.89] 0.009c
Baseline RMDQ score -0.001 [−0.24–0.24] 0.994
Gestational weeksb -0.03 [−0.30–0.24] 0.523
Previous number of children 0.49 [−1.09–2.07] 0.531
Notes:
a Group was coded as 0 = CG and 1 = SG. A negative regression coefﬁcient indicates a smaller change score for the SG,
which indicates a more favourable result for the SG when compared to the CG.
b Recorded gestational weeks at baseline.
c Statistically signiﬁcant at the 0.025 level.
Figure 3 Mean NPRS change scores at each time point, by group. aStatistically signiﬁcant difference
between groups. A negative change score indicates a reduction in pain from baseline.
Full-size DOI: 10.7717/peerj.7080/ﬁg-3
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between the groups (mean difference -2.84; (95% CI [-4.63 to -1.04], R2 = 0.387,
p = 0.003), in favour of the SG group (Table 5).
Differences between the groups in RMDQ change scores at 6 weeks reached statistical
signiﬁcance, with mean (SD) RMDQ change scores in SG and CG of 0.46 (3.05) and
3.64 (3.32), respectively, (Table 3; Fig. 4). These statistically signiﬁcant differences were
maintained after adjusting for baseline scores (pain or disability), gestational weeks and the
number of previous births (mean difference: -3.39; (95% CI [-5.89 to -0.89], R2 = 0.198,
p = 0.009), with the difference favouring the SG (Table 5).
There was no statistically signiﬁcant difference between the SG and CG in PFIQ-7
change scores at 6 weeks (Table 4), when assessed using either unadjusted analyses via
univariable linear regression or adjusted analyses with multivariable linear regression.
PFIQ-7 total score ranges from 0 to 300 and to achieve a minimal clinically important
difference (MCID) is a decrease of 36 points. PFIQ-7 raw scores at 6-weeks indicated that
the SG attained a greater clinical improvement with MCID of 21.8 points compared to the
CG with a MCID of 16.2 points. The SG reported a lesser negative effective with an average
increase in score of 25.7 points compared to the CG reporting an average increase of 50.8
points. Although greater improvements were observed in the SG than the CG, neither
group demonstrated a MCID for the PFIQ-7.
Change scores on the SF-36 Physical Component Summary (SF-36 PCS; Table 4) were
also not signiﬁcantly different between the groups at 6 weeks, either in the univariable
analysis or in the multivariable analysis, which adjusted for baseline factors including
baseline score on the SF-36 PCS, gestational weeks and number of previous births.
Figure 4 Mean RMDQ change scores at each time point, by group. aStatistically signiﬁcant difference
between groups. A negative change score indicates a reduction in disability from baseline.
Full-size DOI: 10.7717/peerj.7080/ﬁg-4
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The MCID for SF-36 PCS and SF-36 MCS is an increase of four points. Both groups
achieved MCID for the SF-36 PCS. The SG demonstrated aMCID of 6.3 points and the CG
a MCID of 9.4 points.
Group allocation was not a signiﬁcant predictor of 6-week change scores on the SF-36
Mental Component Summary (SF-36 MCS; Table 4), in the univariable analysis or when
adjustment was made for baseline scores on the SF-36 MCS, gestational weeks and number
of previous births in the multivariable regression analyses. MCID was demonstrated in
both groups, where the SG achieved a MCID of 7.5 points and the CG a MCID of 5.6
points.
Of the 885 reported daily self-assessed body temperatures in the SG, 883 (99.7%)
ranged between 35.4 and 38.0 C while participants were wearing the DEFOs; two (0.3%)
self-assessed body temperatures were reported to be 39.0 C. There were nil reports of any
ailments for either report of body temperatures at 39.0 C and cessation of wearing the
SRC Pregnancy shorts occurred for one participant for 4 days and then returned to
wearing the garment and monitored as per the research guidelines. The other occurred in
the ﬁnal week of study participation and therefore, did not return to wearing the garment
as the study had been completed with nil reports of any ailments.
DISCUSSION
This prospective quasi-experimental controlled study evaluated for the ﬁrst time the
effectiveness of wearing custom designed compression shorts during pregnancy to manage
prenatal PGP and LBP and associated disability and to further assess the thermal safety of
these compression shorts when they were worn during pregnancy. The study responds
to previous research which has highlighted that LBP and PGP are the most common
conditions experienced by women during pregnancy (Colla, Paiva & Thomaz, 2017;
Hughes et al., 2018; Ho et al., 2009a;Wang et al., 2005). The primary aim of this study was
to examine the effectiveness of a speciﬁc DEFOs for reducing prenatal pain and associated
disability arising from the pelvic girdle and lower back and secondly this study aimed
to further assess the thermal safety of DEFOs during pregnancy.
The main ﬁndings of signiﬁcant differences between groups for the primary outcome
measures, NPRS and RMDQ, indicated that wearing compression shorts during pregnancy
resulted in reductions in pain and in disability related to LBP. After accounting for
potential confounding variables, including the initial pain or disability score amongst other
factors, there was a statistically signiﬁcant difference between the groups in the change in
level of pain and disability that occurred over the 6 weeks following commencement of
participation and wearing of the compression shorts by the SG; the SG experienced
substantially greater pain relief and less disability due to LBP than the CG. Therefore, the
results of the NPRS and RMDQ scores for this study supported the ﬁrst hypothesis that the
use of DEFOs like the SRC Pregnancy Shorts are an effective therapeutic intervention
for the management of pelvic pain and LBP and associated disability in pregnant women.
The management and reduction of pain results found in this study align themselves
with some of the main ﬁndings from previous studies in the literature. Previously
published literature suggests that using supportive/compressive belts and maternity
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garments can be effective in alleviating these conditions (Ho et al., 2009a; Wang et al.,
2005; George et al., 2013; Pennick & Liddle, 2013; Depledge et al., 2005; Ramelet, 2002).
Previous prenatal research has also indicated that DEFOs have a role in the reduction of
back pain in particular instances such as sleeping, walking, working and getting up from a
sitting position (Bertuit et al., 2018; Kalus, Kornman & Quinlivan, 2008).
Despite previous research, the use of individually-ﬁtted compression shorts to reduce
pain and improve functioning during pregnancy has not been previously studied.
Compression shorts may be viewed more favourably than other types of compression belts
and garments during pregnancy, for reasons. These include the minimal time required
to appropriately ﬁt the compression shorts, therefore not negatively impacting on
maternity care provider’s current schedules, the garment being more tolerable and relatively
comfortable to wear under daily attire, and the continued true cross compression
(Doan et al., 2003). The SRC Pregnancy Shorts used in this study are practical and can be
washed as needed to allow optimal results.
Although DEFOs demonstrated to be effective in the reduction of pain and disability,
the results of this study did not show any signiﬁcant differences between groups on the
perceived impact on the participants’ quality of life based on the PFIQ-7 and SF-36 results.
However, the lack of signiﬁcant differences between groups may be explained by the
Hawthorne effect which is where a participant may improve or alter an aspect of their
behaviour or responses during research as a result of acute awareness of being studied
(McCambridge, Witton & Elbourne, 2014). The PFIQ-7 and SF-36 scores were considerably
low at both baseline and at 6 weeks in both the SG and the CG for our study therefore
potentially demonstrating a participant bias of results. The PFIQ-7 and SF-36 ﬁndings in our
study differ from the published literature by Adamczyk et al. (2013). Adamczyk et al. (2013)
reported that based on the results of quality of life questionnaires and health surveys
completed by participants, DEFOs are associated with a high level of treatment satisfaction
and improve a participant’s quality of life. The study did indicate similar results to Adamczyk
et al. (2013) when considering the clinical improvement of the participants as the
PFIQ-7 and SF-36 MCS raw scores at 6 weeks indicated that participants that wore DEFOs
attained a greater clinical improvement reporting a lesser negative effective on the perceived
impact of quality of life than those that did not wear DEFOs. Although a strong conclusion
based on the second hypothesis that perceived quality of life would improve with the use of
DEFOs was not observed perhaps further research inclusive of greater numbers, random
participant allocation, and controlling for factors such as participant bias with improved
self-awareness may present stronger empirical evidence.
Recommendations in the prenatal literature as described by Brearley et al. (2015)
indicate ‘that the safe upper limit for maternal core temperature is 38.9 or 1.5 C above
resting core temperature,’ to prevent possible harm to the foetus (Brearley et al., 2015;
Hartgill, Bergersen & Pirhonen, 2011; Lindqvist et al., 2003). During this study, the
participants remained below this threshold in 99.7% of instances (883 instances) where
body temperature was measured while the compression shorts were worn, with only
two (0.3%) reports of single measurements of body temperature reaching 39.0 C which
were monitored as per normal practice in prenatal care with their maternity care provider.
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A concern for the use of compression garments during pregnancy is the increase in skin
temperature and apprehension that it will raise core body temperature. According to 2016
guidelines from the Royal Australian and New Zealand College of Obstetricians and
Gynaecologists Royal Australian and New Zealand College of Obstetricians and Gynaecologists
(RANZCOG) (2016) a rise in core temperature of less than 1.5 C is widely accepted as safe
during pregnancy and these and other experts routinely advise pregnant women to avoid
overheating to prevent possible harm to the foetus (Royal Australian and New Zealand
College of Obstetricians and Gynaecologists (RANZCOG), 2016; Brearley et al., 2015; Lindqvist
et al., 2003). Previous empirical evidence suggested male and female athletes, aged 19–33, that
the thermoregulatory response to wearing compression garments at recreational and high
levels of training and competition did result in increased skin temperatures (Doan et al.,
2003); however, the associated increases in core temperature were not great enough to have
detrimental effects in ambient and temperate environments with relative humidity
between 46% and 64% (Houghton, Dawson & Maloney, 2009; MacRae et al., 2012).
Therefore, published literature suggests that there are several indications for the use of
DEFOs during pregnancy as an intervention tool and concerns about the negative
implications of increased core temperature for both the woman and foetus has proven to be
safe in not raising core temperature based on high quality evidence available on the use
of compression garments in other ﬁelds of health andmedicine. Based on published evidence
and the appropriate body temperature results of this study it can be suggested that DEFOs
will not affect maternal core temperature and therefore, would be thermally safe to wear
during pregnancy in support of the ﬁnal hypothesis for this study.
Limitations
The small CG size, the lack of randomisation in group allocation, and the relatively large
number of participants lost to follow-up in both groups, mean that the results of this study
should be considered with some caution as our ﬁndings may not have the generalizability to
the wider population and warrant further research. As this study did not have sufﬁcient
numbers to be able to subdivide based on gestational weeks, future research with greater
participant numbers may allow for sub analyses which may result in different clinical
ﬁndings. This study did not include extensive qualitative data collection on DEFOs and
therefore, future research examining the feasibility and acceptability of such garments is
indicated. Nevertheless, the ﬁndings of the current study, as the ﬁrst study to investigate the
effectiveness and thermal safety of using compression shorts during pregnancy, are
promising and indicate that compression shorts are thermally safe, with the study providing
a stepping stone to larger and more rigorous, RCT studies, from an ethical viewpoint.
CONCLUSION
This study demonstrated a reduction in pain and disability associated with common
prenatal ailments when specially-designed and individually-ﬁtted compression shorts were
worn during pregnancy, indicating that these garments constitute a valuable and
effective adjunct to usual healthcare for women during pregnancy. This study did not
demonstrate an increase in the participant’s perception of their quality of life or mental
Szkwara et al. (2019), PeerJ, DOI 10.7717/peerj.7080 17/22
health with use of the compression shorts, but it is possible any such effects were
obscured in the current study by the relatively small sample sizes and losses to follow up
in each group. Further research is therefore needed in these areas. Overall compliance for
wearing the compression shorts during pregnancy was high, indicating women found
the garments acceptable and reasonably comfortable overall. While wearing the compression
shorts, the body temperatures of women remained within the acceptable range, indicating
the compression shorts are thermally safe to wear during pregnancy. Although an
improvement in quality of life was expected but did not occur, the results did indicate that
the majority of women wearing the DEFOs did not experience a dramatic negative effect on
quality of life and either improved slightly or stayed the same.
Clinical implications
The study conﬁrms that specially-designed and individually-ﬁtted compression shorts
like the SRC Pregnancy Shorts are an effective, thermally safe, non-pharmacological
option for the prevention and management of low back and pelvic pain and associated
disability during pregnancy. The results indicate their use is effective in decreasing
numeric pain rating scores and reducing the effects of pregnancy related ailments
such as LBP and PGP on the functional capacity and activities of daily living of women. The
ease of wearing the garment, the ability to adjust the compression garment throughout the
pregnancy and the breathable material make its use recommendable to pregnant women.
Education to maternity care providers with respect to effective use of compression shorts
for addressing common prenatal ailments and complaints may be valuable, as it could
increase the awareness of maternity care providers regarding the effectiveness of these
sorts of compression shorts in minimising the discomfort experienced by women during
pregnancy.
Implications for future research
Pregnancy related LBP and PGP are common ailments experienced by women during
pregnancy and can have a negative impact on their functional capacity, activities of daily
living and overall well-being. As this study was non-randomised and was limited by
participant numbers and loss to follow up, further research is needed to conﬁrm and
extend the ﬁndings in this study so that maternity care providers can have an increased
conﬁdence in the prescription of compression garments.
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